Lundbeck, officially known as H. Lundbeck A/S, is a global pharmaceutical company headquartered in Denmark (DK). Founded in 1915, Lundbeck has established itself as a leader in the neuroscience sector, focusing on the treatment of brain disorders such as depression, schizophrenia, and Alzheimer's disease. With a strong presence in Europe, North America, and Asia, the company is dedicated to improving the lives of patients through innovative therapies. Lundbeck's core products include a range of unique medications that address complex neurological conditions, setting them apart in a competitive market. The company has achieved notable milestones, including the development of several breakthrough treatments that have significantly impacted patient care. Renowned for its commitment to research and development, Lundbeck continues to strengthen its position as a key player in the global pharmaceutical industry.
How does Lundbeck's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Lundbeck's score of 98 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2025, Lundbeck reported total greenhouse gas emissions of approximately 10,670,000 kg CO2e for Scope 1, 2,887,000 kg CO2e for Scope 2, and 65,528,000 kg CO2e for Scope 3, resulting in a combined total of about 13,557,000 kg CO2e for Scope 1 and 2. In 2024, the emissions were approximately 11,547,000 kg CO2e (Scope 1), 3,526,000 kg CO2e (Scope 2), and 66,039,000 kg CO2e (Scope 3), with a total of about 15,073,000 kg CO2e for Scope 1 and 2. For 2023, the figures were significantly higher, with Scope 1 emissions at 20,191,000 kg CO2e, Scope 2 at 7,173,000 kg CO2e, and Scope 3 at 124,338,000 kg CO2e. Lundbeck has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 42% by 2029 from a 2019 baseline, and Scope 3 emissions by 25% within the same timeframe. Long-term goals include a 90% reduction in absolute emissions across all scopes by 2050, also from a 2019 baseline. In addition, Lundbeck's Transition Plan aims to exclusively utilise 100% renewable electricity for all EU sites by 2025, further demonstrating its commitment to sustainability. The company is also working towards ensuring that 100% of its 300 main suppliers use renewable electricity by 2030. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Lundbeck's commitment to addressing climate change within the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 24,954,000 | 0,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 13,832,000 | 00,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Lundbeck has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Lundbeck's sustainability data and climate commitments